



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli, et al.

Serial No.: 08/466,381

Group Art Unit: 1645

Filed : June 6, 1995

Examiner: S. Gucker

For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas
New York, New York 10036
December 12, 2002

Assistant Commissioner for Patents
U.S. Patent and Trademark Office, P.O. Box 2327
Arlington, VA 22202

Attn: Box Sequence

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)


In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted as **Exhibit C** in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing."

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "David J. Kerwick".

David J. Kerwick
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
JPW

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
	10/22/2002		

1 Mo: 11/22/2002
2 Mo: 12/22/2002
3 Mo: 1/22/2003
4 Mo: 2/22/2003
5 Mo: 3/22/2003
6 Mo: 4/22/2003 SML

OCT 28 2002

EXAMINER	
ART UNIT	PAPER NUMBER
	35

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (703) 308-6571. The examiner can normally be reached on Monday to Friday from 0930 to 1800. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623. The fax phone number for this Group is currently (703) 308-4242, but Applicant should confirm this by phoning the Examiner before faxing.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SG

Stephen Gucker

October 17, 2002

Gary L. Kunz
GARY KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

RECEIVED
DEC 30 2002
TECH CENTER 1600/2900



Application No.:08/466,381

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:
- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).


For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RECEIVED



AUG 12 2002

TECH CENTER 1600/2800

1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/08/466,381A

DATE: 08/06/2002

TIME: 17:12:26

Input Set : A:\EP.txt

Output Set: N:\CRF3\08062002\H466381A.raw

Does Not Comply
Corrected Diskette Needed

1 <110> APPLICANT: Israeli, Ron S. Heston,
 -> 2 <120> TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN<130>
 -> 3 <140> CURRENT APPLICATION NUMBER: US 08/466,381<141> 1995-06-06<150> USA
 -> 0 <130> FILE REFERENCE:
 -> 4 <141> CURRENT FILING DATE: 1995-06-06
 -> 4 <151> PRIOR FILING DATE: 1995-03-17<160> 38 <170> PatentIn version 3.1<210> 1<211>

STORED SEQUENCES

sample of submitted file - global
format
errors

5 <212> TYPE: DNA<213> Human<400> 1

-> 6 <210> SEQ ID NO:

-> 6 <211> LENGTH:

-> 6 <213> ORGANISM:

-> 6 <400> SEQUENCE:

6	ctcaaaaggg	ggccggatttc	tttctcttgg	aggcagatgt	tgcctctctc	tctcgctcgg	60
8	attgggttcag	tgcactctag	aaacactgtct	gtgggtggaga	aactggaccc	caggtctggaa	120
10	gcgaatttcca	gcctgcaggg	ctgataagcg	aggcattagt	gagattgaga	gagactttac	180
12	cccgccgtgg	tgggtggagg	gcgcgcagta	gagcagcagc	acaggcgcgg	gtccccgggag	240
14	cccggtctcg	ctcgcgccga	gatgtggaaat	ctccttcacg	aaaccgactc	ggctgtggcc	300
16	acccgcgcgc	gccccgcgtg	gctgtgcgt	ggggcgttgg	tgctggcggg	tggcttcttt	360
18	ctccctcggt	tccttttcgg	gtggtttata	aaatccotcca	atgaagctac	taacattact	420
20	ccaaaggcata	atatgaaagc	atttttggat	gaattgaaag	ctgagaacat	caagaagttc	480
22	ttatataattt	ttacacagat	accacattta	gcaggaacag	aacaaaactt	tcagcttgca	540
24	aagcaaattt	aatcccagtg	gaaagaattt	ggcctggatt	ctgttgagct	agcacattat	600
26	gatgtccctgt	tgttcttaccc	aaataaagact	catccaaact	acatctcaat	aattaatgaa	660
28	gatggaaatg	agattttcaa	cacatcatta	tttgaaccac	ctcctccagg	atatgaaaat	720
30	gtttcggtata	tttgttaccacc	tttcagtgtct	ttctcttcctc	aaggaatgcc	agagggcgat	780
32	ctagtgtatg	ttaactatgc	acgaactgaa	gacttctta	aatttggaaacg	ggacatgaaa	840
34	atcaatttgc	ctggggaaaat	tgttaatttgc	agatatggaa	aagtttcag	agggaaaataag	900
36	gttaaaaatg	cccagctggc	agggggccaaa	ggagtcatcc	tctactccga	ccctgctgac	960
38	tactttgtct	ctgggggtgaa	gtcctatcca	gatgggttgc	atcttcctgg	aggtgggtgc	1020
40	cagcgtgaaat	atatcctaaa	tctgaatgtt	gcaggagacc	ctctcacacc	aggttaccca	1080
42	gcaaatttgc	atgttatacg	gctgtggattt	gcagaggctg	ttggttttcc	aagtatttct	1140
44	gttcatccaa	ttggataacta	tgatgcacag	aagcttctag	aaaaaatggg	tggctcagca	1200
46	ccaccagata	gcagctggag	aggaagtctc	aaagtgcctt	acaatgttgg	acctggcttt	1260
48	actggaaaact	tttctacaca	aaaagtcaag	atgcacatcc	actctaccaa	tgaagtgaca	1320
50	agaatttaca	atgtgatagg	tactctcaga	ggagcagttt	aaccagacag	atatgtcatt	1380
52	ctggggaggtc	accgggactc	atgggtgttt	ggtggatttg	accctcagag	tggagcagct	1440
54	gttggatcgat	aaatttgcag	gagctttgg	acactgaaaa	aggaagggtg	gagacctaga	1500
56	agaacaattt	tgtttgcag	ctgggatgca	gaagaatttg	gtcttcttgg	ttctacttgag	1560
58	tgggcagagg	agaatttcaag	actccttcaa	gagcgtggcg	tggcttataat	taatgtgac	1620
60	tcatctatag	aggaaacta	cactctgaga	gttgatttgc	caccgctgat	gtacagcttg	1680